PDF(Pubmed)
Abstract：
UNASSIGNED: Cutaneous manifestations of hematological neoplasms can be divided into three broad categories - direct infiltration, paraneoplastic conditions, and those due to the treatment of hematological cancers.
UNASSIGNED: To study the frequency and patterns of mucocutaneous manifestations in patients with hematolymphoid neoplasms and those due to chemotherapy.
UNASSIGNED: This was an observational study done with 172 patients. Categorization of mucocutaneous manifestations was done into malignancy-associated and chemotherapeutic drugs-associated and data was analyzed.
UNASSIGNED: Out of a total of 172 patients, 15.6% (27/172) had malignancy-related mucocutaneous manifestations. Among these, 4.6% (8/172) had direct infiltration of malignant cells into the skin and 11% (19/172) had paraneoplastic manifestations. The most common chemotherapy-related mucocutaneous manifestations were nail changes - 47.1% (81/172), of which transverse melanonychia was the most common (20.9%). About 44.2% (76/172) had a cutaneous infection, the commonest of which was a fungal infection (15.1%). Chemotherapy-induced alopecia was noted in 46.5% (80/172) and found to be significantly associated with cytarabine, daunorubicin, doxorubicin, methotrexate, and vincristine. Cutaneous hyperpigmentation was found to be significantly associated with cytarabine, doxorubicin, and vincristine.
UNASSIGNED: Mucocutaneous manifestations cause additional discomfort to a patient undergoing chemotherapy. Early recognition and timely and appropriate management facilitate symptom control and prevent treatment-related morbidity. A multidisciplinary approach involving hemato-oncologists and dermatologists can help achieve this target.
UNASSIGNED: To study the frequency and patterns of mucocutaneous manifestations in patients with hematolymphoid neoplasms and those due to chemotherapy.
UNASSIGNED: This was an observational study done with 172 patients. Categorization of mucocutaneous manifestations was done into malignancy-associated and chemotherapeutic drugs-associated and data was analyzed.
UNASSIGNED: Out of a total of 172 patients, 15.6% (27/172) had malignancy-related mucocutaneous manifestations. Among these, 4.6% (8/172) had direct infiltration of malignant cells into the skin and 11% (19/172) had paraneoplastic manifestations. The most common chemotherapy-related mucocutaneous manifestations were nail changes - 47.1% (81/172), of which transverse melanonychia was the most common (20.9%). About 44.2% (76/172) had a cutaneous infection, the commonest of which was a fungal infection (15.1%). Chemotherapy-induced alopecia was noted in 46.5% (80/172) and found to be significantly associated with cytarabine, daunorubicin, doxorubicin, methotrexate, and vincristine. Cutaneous hyperpigmentation was found to be significantly associated with cytarabine, doxorubicin, and vincristine.
UNASSIGNED: Mucocutaneous manifestations cause additional discomfort to a patient undergoing chemotherapy. Early recognition and timely and appropriate management facilitate symptom control and prevent treatment-related morbidity. A multidisciplinary approach involving hemato-oncologists and dermatologists can help achieve this target.
摘要：
■血液肿瘤的皮肤表现可分为三大类-直接浸润，副肿瘤条件，和那些由于血液癌症的治疗。
■研究血淋巴样肿瘤患者和化疗患者皮肤粘膜表现的频率和模式。
■这是一项对172名患者进行的观察性研究。将皮肤粘膜表现分为恶性肿瘤相关和化疗药物相关，并对数据进行分析。
■在总共172名患者中，15.6%(27/172)有恶性肿瘤相关的皮肤黏膜表现。其中,4.6%(8/172)有恶性细胞直接浸润皮肤，11%(19/172)有副肿瘤表现。最常见的化疗相关皮肤粘膜表现是指甲改变-47.1％（81/172），其中最常见的是横断性甲甲(20.9%)。约44.2%(76/172)有皮肤感染,其中最常见的是真菌感染（15.1%）。化疗诱导的脱发在46.5%(80/172)中被发现与阿糖胞苷显著相关,柔红霉素,阿霉素,甲氨蝶呤,还有长春新碱.发现皮肤色素沉着过度与阿糖胞苷显著相关，阿霉素,还有长春新碱.
■皮肤粘膜表现会给接受化疗的患者带来额外的不适。早期识别和及时适当的管理有助于症状控制和预防与治疗相关的发病率。涉及血液肿瘤学家和皮肤科医生的多学科方法可以帮助实现这一目标。
■研究血淋巴样肿瘤患者和化疗患者皮肤粘膜表现的频率和模式。
■这是一项对172名患者进行的观察性研究。将皮肤粘膜表现分为恶性肿瘤相关和化疗药物相关，并对数据进行分析。
■在总共172名患者中，15.6%(27/172)有恶性肿瘤相关的皮肤黏膜表现。其中,4.6%(8/172)有恶性细胞直接浸润皮肤，11%(19/172)有副肿瘤表现。最常见的化疗相关皮肤粘膜表现是指甲改变-47.1％（81/172），其中最常见的是横断性甲甲(20.9%)。约44.2%(76/172)有皮肤感染,其中最常见的是真菌感染（15.1%）。化疗诱导的脱发在46.5%(80/172)中被发现与阿糖胞苷显著相关,柔红霉素,阿霉素,甲氨蝶呤,还有长春新碱.发现皮肤色素沉着过度与阿糖胞苷显著相关，阿霉素,还有长春新碱.
■皮肤粘膜表现会给接受化疗的患者带来额外的不适。早期识别和及时适当的管理有助于症状控制和预防与治疗相关的发病率。涉及血液肿瘤学家和皮肤科医生的多学科方法可以帮助实现这一目标。
